Meeting
2023 ASCO Annual Meeting
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
Authors
Danny Nguyen
City of Hope- Long Beach Elm, Long Beach, CA
Danny Nguyen , Elaine Shum , Christina S Baik , Pasi A. Janne , Jyoti D. Patel , Erin Lynn Schenk , Yuji Shibata , Helena Alexandra Yu , Faris Albayya , Paul Pearson , Minjie Feng , Melinda Louie-Gao , Alena Zalutskaya , Alexander I. Spira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05241873
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9064)
DOI
10.1200/JCO.2023.41.16_suppl.9064
Abstract #
9064
Poster Bd #
52
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
First Author: Joel W. Neal
Poster
2022 ASCO Annual Meeting
Phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations.
First Author: Alexander I. Spira
Poster
2020 ASCO Virtual Scientific Program
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
First Author: Keunchil Park
Poster
2015 ASCO Annual Meeting
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
First Author: David S. Hong